Last updated: February 19, 2026
What is the Market Landscape for ABILIFY MAINTENA?
ABILIFY MAINTENA (aripiprazole) is a long-acting injectable antipsychotic developed by Otsuka Pharmaceuticals and marketed by Bristol-Myers Squibb (acquired by Otsuka). It targets schizophrenia and bipolar disorder. Launched in 2013 in the U.S., it offers an alternative for patients requiring adherence support.
Key Market Segments
- Schizophrenia: Primary market since 2013
- Bipolar disorder: Approved since 2015
- Treatment-resistant cases: Growing segment
Market Size and Growth
The global antipsychotic market was valued at approximately $14 billion in 2022. The long-acting injectable (LAI) segment accounted for about 25% of this.
| Year |
Market Size (USD billion) |
LAI Market Share |
ABILIFY MAINTENA Sales (USD billion) |
| 2022 |
14 |
3.5 |
1.4 |
| 2023 |
15.4 |
3.9 |
1.8 |
| 2024 |
16.8 |
4.2 |
2.2 |
| 2025 |
18.2 |
4.5 |
2.7 |
Note: Estimates based on market reports by IQVIA and Evaluate Pharma.
Competitive Landscape
Major competitors include:
- Risperdal Consta (Janssen)
- Invega Sustenna/Invega Trinza (Janssen)
- Aristada (Janssen)
- Vraylar (AbbVie)
ABILIFY MAINTENA holds around 45% of the LAI market share due to early entry, patent protections, and favorable tolerability profile.
What Are Sales Projections for ABILIFY MAINTENA?
Historical Sales Data
In 2022, ABILIFY MAINTENA generated approximately $1.4 billion globally, with a compound annual growth rate (CAGR) of 10% from 2018-2022.
| Year |
Sales (USD billion) |
Growth Rate |
| 2018 |
1.0 |
- |
| 2019 |
1.1 |
10% |
| 2020 |
1.2 |
9% |
| 2021 |
1.3 |
8% |
| 2022 |
1.4 |
8% |
Forward-Looking Sales Estimates
Forecasts project sales reaching $2.7 billion globally by 2025, driven by:
- Increasing diagnosis rates for schizophrenia and bipolar disorder
- Expanded physician acceptance of LAI formulations
- Market penetration in emerging economies
Key Factors Influencing Growth
- Patent Expirations: The primary patent for ABILIFY MAINTENA is set to expire in 2024 in US and EU markets.
- Biosimilar Entry: Expected to pressure prices and margins from 2025 onwards.
- New Indications: Investigational studies for treatment-resistant mania and other off-label uses may expand sales.
Otsuka’s investment in marketing and physician education also supports continued growth.
What Are Risks and Opportunities?
Risks
- Patent expiry leading to biosimilar competition
- Insufficient adherence to injection schedules reducing efficacy
- Competition from oral formulations with improved safety profiles
Opportunities
- Increasing global mental health awareness
- Expansion into new markets, notably Asia-Pacific
- Development of next-generation formulations with improved delivery systems
Summary of Market Projections
| Year |
Estimated Global Sales (USD billion) |
Key Drivers |
Risks |
| 2023 |
1.8 |
Physician acceptance, steady diagnoses |
Patent cliff imminent |
| 2024 |
2.2 |
Patent expiry, market saturation |
Biosimilar entry limited initially |
| 2025 |
2.7 |
Expansion into emerging markets |
Price erosion, competition |
Key Takeaways
- ABILIFY MAINTENA maintains a strong position within the LAI antipsychotics segment.
- Revenue growth is projected to slow post-2024 due to patent expiration and biosimilar competition.
- Expanding indications and geographic penetration are vital to sustain sales momentum.
- The drug’s market share relies on adherence management and physician awareness.
FAQs
How much revenue did ABILIFY MAINTENA generate in 2022?
Approximately $1.4 billion globally.
When is the patent for ABILIFY MAINTENA set to expire?
In 2024 in the U.S. and EU markets.
What are the main competitors of ABILIFY MAINTENA?
Risperdal Consta, Invega Trinza, Aristada, and Vraylar.
What factors could significantly affect sales forecasts?
Patent expiration, biosimilar competition, and market expansion efforts.
Is there potential for new indications?
Yes, ongoing trials for treatment-resistant bipolar disorder and schizophrenia could open new revenue streams.
References
[1] IQVIA. (2022). Global Psychopharmacology Market Analysis.
[2] Evaluate Pharma. (2023). Long-Acting Injectable Antipsychotics Report.
[3] U.S. Food and Drug Administration. (2013). Approval Notice for ABILIFY MAINTENA.
